Novo Nordisk’s Legal Blitz and Discounted Ozempic Copy Signal a New Phase in the GLP-1 Wars
The Danish pharmaceutical giant is firing on multiple fronts — in the courtroom, on the pricing front, and…
Novo Nordisk’s Buyback Blitz Masks Building Pressure Ahead of 2027 Price Cuts
The Danish pharmaceutical heavyweight is buying back shares at a record pace, yet the same weekly disclosures that…
Novo Nordisk’s Buyback Blitz Runs Alongside a Parent’s Billion-Dollar Exit
The Danish pharma heavyweight is keeping its share repurchase engine running at full throttle — and the timing…
Novo Nordisk’s Two-Front Data Blitz: Oral Wegovy Scores in Weight Loss as MASH Findings Bolster th
Novo Nordisk’s oral semaglutide shows 21.6% weight loss in early responders, but stock remains 45% off highs amid…
Novo Nordisk’s Buyback Blitz and Oral Wegovy Surge Counter a Bruising Year
Novo Nordisk pushes forward with a DKK 15 billion buyback and oral Wegovy success, while high-dose injectable data…
Novo Nordisk’s Oral Wegovy Pill Defies Expectations as Data Blitz Reshapes Obesity Market Battle
Novo Nordisk’s oral Wegovy pill nearly doubled sales forecasts, with Istanbul congress data showing early responders achieve 21.6%…
European Lithium’s Rare Earth Blitz Advances in Greenland as Merger Math and Austrian Woes Temper th
European Lithium stock surges 205% YTD, but faces headwinds: Morgan Stanley exits, A$24M shortfall for Critical Metals merger,…
Novo Nordisk’s Pipeline Push and Buyback Blitz Face a Reckoning at Q1 Earnings
Novo Nordisk faces a pivotal Q1 earnings test amid share buybacks, pipeline diversification beyond semaglutid, and cautious analyst…
Novo Nordisk’s Buyback Blitz and FDA Fast-Track Mask a Steep Profit Slide
Novo Nordisk spends billions on share repurchases but faces a 50% stock drop, 2026 revenue decline, and fierce…